Yanbin Cai

Yanbin Cai

Auto-generated profile, based on publicly available information

Yanbin Cai

Guangdong Provincial Biomedical Engineering Technology Research Center for Cardiovascular Disease Department of Cardiology and Laboratory of Heart Center Zhujiang Hospital Southern Medical University Guangzhou 510280 China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2022 in Acta Biomaterialia
Verified
Journal Article
Closed access
XLXu Liao
Xu Liao
XSXudong Song
Xudong Song
JLJiejing Li
Jiejing Li
LLLisha Li
Lisha Li
XFXianglin Fan
Xianglin Fan
YCYanbin Cai
Yanbin Cai

7 January 2021 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
YZYuanzhi Zhong
Yuanzhi Zhong
JZJie Zhan
Jie Zhan
GXGuanghui Xu
Guanghui Xu
YCYumiao Chen
Yumiao Chen
QQQin Qin
Qin Qin
YCYanbin Cai
Yanbin Cai

6 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
WZWeiqi Zhang
Weiqi Zhang
YZYinghua Zeng
Yinghua Zeng
QXQiuqun Xiao
Qiuqun Xiao
YWYuanyuan Wu
Yuanyuan Wu
JLJiale Liu
Jiale Liu
YCYanbin Cai
Yanbin Cai
Targeted immunomodulation for reactivating innate cells, especially macrophages, holds great promise to complement current adaptive immunotherapy. Nevertheless, there is still a lack of high-performance therapeutics for blocking macrophage phagocytosis checkpoint inhibitors in solid tumors. Herein, a peptide-antibody combo-supramolecular in situ assembled CD47 and CD24 bi-target inhibitor (PAC-SABI) is described, which undergoes biomimetic surface propagation on cancer cell membranes through ligand-receptor binding and enzyme-triggered reactions. By simultaneously blocking CD47 and CD24 signaling, PAC-SABI enhances the phagocytic ability of macrophages in vitro and in vivo, promoting anti-tumor responses in breast and pancreatic cancer mouse models. Moreover, building on the foundation of PAC-SABI-induced macrophage repolarization and increased CD8+ T cell tumor infiltration, sequential anti-PD-1 therapy further suppresses 4T1 tumor progression, prolonging survival rate. The in vivo construction of PAC-SABI-based nano-architectonics provides an efficient platform for bridging innate and adaptive immunity to maximize therapeutic potency.


4 February 2014 in Analytical Chemistry
Verified
Journal Article
Closed access
YCYanbin Cai
Yanbin Cai
YSYang Shi
Yang Shi
HWHuaimin Wang
Huaimin Wang
JWJingyu Wang
Jingyu Wang
DDDan Ding
Dan Ding
ZYZhimou Yang
Zhimou Yang

30 May 2019 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
TXTengyan Xu
Tengyan Xu
YCYanbin Cai
Yanbin Cai
XZXinglong Zhong
Xinglong Zhong
LZLe Zhang
Le Zhang
DZDebing Zheng
Debing Zheng
ZYZhimou Yang
Zhimou Yang
The identification and removal of senescent cells is very important to improve human health and prolong life. In this study, we introduced a novel strategy of β-galactosidase (β-Gal) instructed peptide self-assembly to selectively form nanofibers and hydrogels in senescent cells. We demonstrated that the in situ formed nanofibers could alleviate endothelial cell senescence by reducing p53, p21, and p16INK4a expression levels. We also demonstrated that our strategy could selectively remove senescent endothelial cells by inducing cell apoptosis, with an increase in the BAX/BCL-2 ratio and caspase-3 expression. Our study reports the first example of enzyme-instructed self-assembly (EISA) by a sugar hydrolase, which may lead to the development of supramolecular nanomaterials for the diagnosis and treatment of many diseases, such as cancer, and for other applications, such as wound healing and senescence.